Skip to main content

Thorp Clay

No open-market purchases or sales filed in the past year.

Current role at each company

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought
–
0 filings
Sold
–
0 filings
Net
–
Bought minus sold
Companies
0
With open-market trades

Trades

Every Form 4 that lists Thorp Clay as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

CLSD Clearside Biomedical, Inc.

Director4 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Dec 19, 2022 (view filing)Feb 10, 2021677 daysThorp ClayDirectorSSale−32.9K$4.43−$145.6K−0.7%4.95M afterAmended
Dec 21, 2022 (view filing)Dec 21Same dayThorp ClayDirectorPPurchase+14.0K$1.02+$14.3K+84.7%30.5K after
Sep 25, 2023 (view filing)Sep 25Same dayThorp ClayDirectorPPurchase+10.0K$0.86+$8.60K+32.8%40.5K after
Feb 24, 2025 (view filing)Feb 24Same dayThorp ClayDirectorPPurchase+15.0K$0.92+$13.8K+9.3%176.1K after

VIGL Vigil Neuroscience, Inc.

Director3 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jan 11, 2022 (view filing)Jan 11Same dayThorp ClayDirectorPPurchase+265.0K$14.00+$3.71M+21.1%1.52M after
Mar 28, 2022 (view filing)Mar 28Same dayThorp ClayDirectorPPurchase+3.00K$7.20+$21.6KNew position3.00K after
May 17, 2022 (view filing)May 16-171 dayThorp ClayDirectorPPurchase+36.7K$2.85+$104.4K+2.4%1.56M after2 lots

PHAS PhaseBio Pharmaceuticals Inc

Director1 trade

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 18, 2021 (view filing)Aug 18Same dayThorp ClayDirectorPPurchase+10.0K$3.00+$30.0K+43.6%32.9K after